Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40VJX | ISIN: US89357L4023 | Ticker-Symbol:
NASDAQ
28.03.25
20:44 Uhr
0,527 US-Dollar
+0,007
+1,35 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRANSCODE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TRANSCODE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TRANSCODE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC13854First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being...
► Artikel lesen
DiTranscode Therapeutics, Inc. - 8-K, Current Report1
DiTransCode Therapeutics Announces $10M Stock And Warrant Offering1
MoTransCode Therapeutics stock slides after announces to raise $10M securities offering5
21.03.TransCode Therapeutics Stock Surges 85%15
21.03.Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc.471BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at...
► Artikel lesen
13.03.TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy5
13.03.TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial145Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3 No significant...
► Artikel lesen
TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln
25.02.TransCode Therapeutics, Inc. Announces Results of Special Meeting534BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more...
► Artikel lesen
25.02.Transcode Therapeutics, Inc. - 8-K, Current Report6
06.02.TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial241No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb....
► Artikel lesen
24.01.TransCode Therapeutics Shares Are Surging Today: What's Going On?15
07.01.TransCode Therapeutics regains compliance with Nasdaq5
20.12.24Transcode Therapeutics, Inc. - 8-K, Current Report1
18.12.24TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial188Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities...
► Artikel lesen
06.12.24Transcode Therapeutics, Inc. - S-1, General form for registration of securities11
02.12.24Transcode Therapeutics, Inc. - 8-K, Current Report1
02.12.24Why TransCode Therapeutics (RNAZ) Stock Is Diving8
02.12.24TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 42
29.11.24TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split306BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1